Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled IBIO123 for Mild to Moderate COVID-19
NCT05298813Phase 2Completed
- Sponsor
- Immune Biosolutions
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of IBIO123 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Immune Biosolutions. Primary endpoints: Safety and tolerability of IBIO123 compared to placebo at Day 29 and SARS-CoV-2 viral load and viral clearance at Day 7. Started Sep 2021; status: completed.
02
Drugs
IBIO123
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05298813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298813.